Duloxetine Metabolism and Fibromyalgia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Utah

About this trial

People with fibromyalgia report generalized body pain ("pain all over"), increased sensitivity to painful stimulation, chronic tiredness or low energy, sleep problems, and other physical and functional problems. The exact cause of the disorder is poorly understood, and treatment can be difficult.

The degree to which duloxetine is helpful for people with fibromyalgia varies greatly. For some people, it is very helpful for managing fibromyalgia symptoms. For others, people may not notice any benefit. Yet for some, it is a little helpful and the effect is noticeable only when people forget to take the medicine.

The purpose of this study is to collect data to better understand the relationship among gene types that control those enzymes, blood concentrations of duloxetine, and how it helps the symptoms.

Eligibility criteria

Qualifiers

Adults 18+

Meeting diagnostic criteria for Fibromyalgia

Patients taking Duloxetine 60 mg/day for at least 8 weeks

Disqualifiers

Pregnant patients per verbal confirmation

Patients that have a history of physician diagnosed kidney or liver disfunction or history of renal dialysis.

Patients requiring an interpreter to communicate

Patient's with progressive illnesses other than fibromyalgia that have a chronic pain and fatigue component (e.g., cancer patients receiving antineoplastic treatment, Parkinson's disease, Multiple Sclerosis).

Trial design

Treatments tested in this trial

  • Observational

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators